JCB logo
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published 6 January 2003. doi:10.1083/jcb.200206079
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 2014K)
Right arrow PPT slides of all figures
Right arrow Supplemental Material Index
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JCB
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Innocenti, M.
Right arrow Articles by Scita, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Innocenti, M.
Right arrow Articles by Scita, G.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

© The Rockefeller University Press, 0021-9525/2003/1/17 $5.00
The Journal of Cell Biology, Volume 160, Number 1, 17-23


Report

Phosphoinositide 3-kinase activates Rac by entering in a complex with Eps8, Abi1, and Sos-1



Metello Innocenti1, Emanuela Frittoli1, Isabella Ponzanelli1, John R. Falck2, Saskia M. Brachmann3,4, Pier Paolo Di Fiore1,5,6 and Giorgio Scita1

1 Department of Experimental Oncology, European Institute of Oncology, 20141 Milan, Italy
2 Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX 75390
3 Division of Signal Transduction, Beth Israel Deaconess Medical Center, Harvard Institute of Medicine, Boston, MA 02115
4 Freie Universitaet Berlin, Institut fuer Bohemia, 14195 Berlin, Germany
5 The FIRC Institute for Molecular Oncology (IFOM), 20134 Milan, Italy
6 Dipartimento di Medicina Chirurgia ed Odontoiatria, Universitá degli Studi di Milano, 20122 Milano, Italy

Address correspondence to Giorgio Scita, Dept. of Experimental Oncology, European Institute of Oncology, Via Ripamonti, 435, 20141 Milan, Italy. Tel.: 39-0257489825. Fax: 39-0257489851. E-mail: gscita{at}ieo.it

Class I phosphoinositide 3-kinases (PI3Ks) are implicated in many cellular responses controlled by receptor tyrosine kinases (RTKs), including actin cytoskeletal remodeling. Within this pathway, Rac is a key downstream target/effector of PI3K. However, how the signal is routed from PI3K to Rac is unclear. One possible candidate for this function is the Rac-activating complex Eps8–Abi1–Sos-1, which possesses Rac-specific guanine nucleotide exchange factor (GEF) activity. Here, we show that Abi1 (also known as E3b1) recruits PI3K, via p85, into a multimolecular signaling complex that includes Eps8 and Sos-1. The recruitment of p85 to the Eps8–Abi1–Sos-1 complex and phosphatidylinositol 3, 4, 5 phosphate (PIP3), the catalytic product of PI3K, concur to unmask its Rac-GEF activity in vitro. Moreover, they are indispensable for the activation of Rac and Rac-dependent actin remodeling in vivo. On growth factor stimulation, endogenous p85 and Abi1 consistently colocalize into membrane ruffles, and cells lacking p85 fail to support Abi1-dependent Rac activation. Our results define a mechanism whereby propagation of signals, originating from RTKs or Ras and leading to actin reorganization, is controlled by direct physical interaction between PI3K and a Rac-specific GEF complex.

Key Words: PI3K; RTK; actin remodeling; signaling; GEF


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents